2020 Flashcards
3 investigations that would help with HES diagnosis, and 2 mutations
Hypereosinophila
3 investigations
- Bone marrrow biopsy for specific stains such as PDGFRA-1 and PDGFRB2
- IgE level
- LSUB for CD3-CD4+ which is associated with L-HES subtypes
Mutation
- JAK2
- FGFR
- PDGFRA-1 and PDGFRB-2
Role of filaggrin mutation, how does it contribute to AD?
- filaggrin mutation leads to decreases integrity of the skin barrier function
- this contributes to AD bc of impaired moisturizuration of the skin enhanced infectious inflammation and breaches in the skin barrier
4 reasons for poor AD control
- poor compliance
- poor understanding of the treatment plan
- Underlying contributers to the diagnosis such as PID or nutritional deficiencies (zinc)
- inadequate dosing
- wrong diagnosis
Scoring systems in AD
- EASI - measures extent of body SA affected
- uses number score for redness, thickening, scratching, lichenification - SCORAD - uses rule of 9s to measure extent of eczema
- POEM - (pt oriented eczema measure)
- questionaries that measure days of the week involvement of eczema sx
Global suppression after measles, what lab changes do you expect
- T cell lymphopenia
- poor T cell response to mitogens
- ?decreases Abs
investigations in sarcoidosis
- HRCT
- BAL
- bronchoscopy and biopsy
biologic used in sarcoidosis
Inflixumab
stages of HP and imaging finding
- Acute
- CXR normal
- PFTs restrictive,
- HRCT shows mediastinal lymphadenopathy and ground glass opacities - Subacute
- HRCT: micronodular pattern on HRCT - Chronic
- fibrotic lung disease, w clubbing and hypoxia
- HRCT: honey combing, air trapping, and micronodules
histology of HP
- poorly formed non caseating granulomas or mononuclear infiltrates with giant cells
Target and MOA of Dupilumab
IgG4 binds to IL-4R, which inhibits IL4 and IL13
MOA - by binding to IL4 and IL13 it decreases the cytokines that mediate AD
CRSwNP - what are two cytokines involved and two tx other than INCS
IL4, IL5
mab treatment -
- Xolair (18+)
- Dupilumab (18+)
- Mepolizumab (18+ w CRwNP)
Indications for Nucala (Mepolizumab)
- add on maintenance tx for > 6 year olds with severe asthma and with an eosinophilic phenotype
- add on maintenance for of adult patients 18+ with CRSwNP
- treatment of adults with EGPA
- treatment of adults and peds > 12 years with HES for > 6 months without an identifiable non-hematological 2 cause
dosing 12+ - 100 mg SC Q4weeks 6-11 - 40 mg SC Q4weeks CRSwNP 100 mg SC Q4 weeks EGPA 300 mg (100mg injections sep) Q4 weeks
occupational asthma from nail salon
- what is the allergen
- 3 mechanisms
- acrylamides
- immune mediated - IgE mediated
non-immune mediated - reactive airway dysfunction syndrome
irritant - irritant chemical, dust, fumes
OIT major antibody and mechanism of tolerance
Major antibody - IgG4
- shift from TH2 cytokine release to TH1
- increase in IgG4
- increase in IL-10 and TGF b
these actions lead to T cell anergy which contributes to OIT
what are the consequences of venom IT
decreased IgE
increased IgG4
increased IL10 and TGFB
when would you not skin test in VIT? different methods?
- Overlying skin infection
- Patient did not d/c appropriate medications (AH or INAH)
- Patient has previous anaphylaxis to skin testing
- Dermatographism
- SPT with 100 mcg/ml
- ID with 1 mcg/ml
- sIgE